Liver humanized NSG-PiZ mice support the study of chronic hepatitis B virus infection and antiviral therapies
Colon-Thillet, R.; Stone, D.; Loprieno, M. A.; Klouser, L.; Roychoudhury, P.; Santo, T. K.; Xie, H.; Stensland, L.; Upham, S. L.; Pepper, G.; Huang, M.; Aubert, M.; Jerome, K. R.
Show abstract
Hepatitis B virus (HBV) is a pathogen of major public health importance that is largely incurable once a chronic hepatitis B (CHB) infection is established. Only humans and great apes are fully permissive to HBV replication, and this species restriction has impacted HBV research by limiting the utility of small animal models of HBV. To combat the species restriction of HBV and enable more HBV studies in vivo, liver-humanized mouse models have been developed that harbor primary human hepatocytes (PHH) and are fully permissive to HBV infection and replication. Unfortunately, these models can be difficult to establish and are expensive commercially, which has limited their academic use. As an alternative mouse model to study HBV, we evaluated liver-humanized NSG-PiZ mice and showed that they are fully permissive to HBV and can develop CHB. Mice were infected with a precore mutant clinical isolate that has now been serially passaged through 3 generations of mice without loss of fitness. HBV selectively replicates in hCK18+ human hepatocytes within chimeric livers, and HBV+ mice secrete infectious virions and HBsAg into blood, while also harboring covalently closed circular DNA (cccDNA). HBV+ mice remain viremic for at least 169 days, which should enable the study of new curative therapies targeting CHB and respond to antiviral entecavir therapy. The extended duration of viremia is sufficient to enable the study of established and new therapeutic approaches targeting CHB. Furthermore, HBV+ PHH in NSG-PiZ mice can be transduced by the hepatotropic AAV3b and AAV.LK03 vector capsids, which should enable the study of curative gene therapies that target CHB. In summary, our data demonstrates that liver humanized NSG-PiZ mice can be used as a robust and cost-effective alternative to existing CHB models and may enable more academic research labs to study HBV disease pathogenesis and antiviral therapy in a setting that is fully permissive to ongoing replication.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Harnessing the power of whole human liver ex situ normothermic perfusion for preclinical AAV vector evaluation 95%
- In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions 94%
- Precision Cas9 Genome Editing in vivo with All-in-one, Self-targeting AAV Vectors 93%
Similar papers in this journal
Similar papers in this journal
- Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates 91%
- Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2 91%
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice 91%
Similar papers in this journal
- The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice 95%
- An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma 93%
- Liver Sinusoidal Endothelial Cells and Laminin dictate cholangiocytes fate in chronic liver disease 91%
Similar papers in this journal
- Human liver organoids; a patient-derived primary model for HBV Infection and Related Hepatocellular Carcinoma 95%
- Elys deficiency constrains Kras-driven tumour burden by amplifying oncogenic stress 92%
- Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.